Miles Wang, a researcher at OpenAI whose work focuses on using artificial intelligence to accelerate scientific discovery, is in talks to launch a new startup dedicated to AI-powered drug discovery, valued at approximately $2 billion. Wang is seeking to raise about $200 million in funding, with venture capital firm Lightspeed reportedly in discussions to lead the round. Several other OpenAI researchers are expected to join the new company, marking another instance of talent migration from the ChatGPT maker to specialized AI ventures.

Why Is OpenAI Talent Moving Into Drug Discovery?

Wang's departure reflects a broader trend of applying large language models (LLMs), which are AI systems trained on vast amounts of text data to understand and generate human language, to solve real-world problems in life sciences. His research at OpenAI has centered on how AI models can automate and accelerate scientific discovery, making him a natural fit to lead a biotech-focused venture. The timing is significant; investor appetite for AI-driven drug discovery has grown substantially, with multiple competing startups raising enormous funding rounds in recent months.

The competitive landscape underscores the opportunity. Chai Discovery, a two-year-old startup developing AI models that predict molecular interactions to identify new drugs, raised $400 million at a $3.8 billion valuation, according to an announcement on Tuesday. Google DeepMind spinoff Isomorphic Labs, which also develops AI models for drug discovery, secured a $2.1 billion Series B funding round in May. These figures demonstrate that investors see genuine commercial potential in automating parts of the drug development process.

What Problem Does Wang's Startup Aim to Solve?

Wang's new company may focus on identifying new uses for existing drugs and potentially reviving medications that failed in earlier clinical trials, according to sources familiar with the plans. This approach has a significant advantage over developing entirely new drugs from scratch: FDA-approved medications have already been tested for safety, which can dramatically shorten the path to market and revenue. Finding new therapeutic applications for existing drugs, sometimes called drug repurposing, is a strategy that can reduce both development time and financial risk.

Wang joined OpenAI in 2024 after leaving Harvard, where he was pursuing a bachelor's degree in computer science. His trajectory reflects a shift in venture capital attitudes; investors have become increasingly comfortable backing young founders who have not completed traditional college degrees, particularly when those founders have demonstrated expertise in high-demand fields like AI research.

How AI Is Transforming Drug Discovery

• Molecular Prediction: AI models can predict how molecules interact with biological targets, helping researchers identify promising drug candidates without conducting as many physical experiments in the laboratory.
• Accelerated Timelines: By automating the screening and analysis of potential drug compounds, AI reduces the time required to move from initial discovery to clinical testing, potentially cutting years off traditional development cycles.
• Drug Repurposing: AI can analyze existing FDA-approved drugs to discover new therapeutic uses, allowing companies to bring treatments to market faster since safety data already exists.

The convergence of large language models, machine learning, and biotech expertise is creating a new category of startups that sit at the intersection of software and life sciences. Unlike traditional pharmaceutical companies that rely on decades of chemical synthesis and animal testing, AI-first drug discovery startups can leverage computational power to explore vastly larger chemical spaces and identify patterns humans might miss.

Wang disputed some of the funding figures and company details reported by TechCrunch but did not provide corrected numbers or specifics. Lightspeed Venture Partners did not respond to requests for comment. While the deal remains in discussion and details could change, the story signals that OpenAI's talent pool continues to be a source of founders and leaders for emerging AI applications beyond conversational chatbots.

The exodus of OpenAI researchers into specialized ventures also reflects the maturation of the AI industry. As large language models become more commoditized and competitive, researchers and entrepreneurs are increasingly focused on applying these tools to vertical markets like healthcare, where the potential impact and financial returns can be substantial. Wang's move suggests that the next wave of AI-driven innovation may come not from building bigger, more general-purpose models, but from applying existing AI capabilities to solve specific, high-value problems in regulated industries.